• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

artificial intelligence

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

November 7, 2022 by SharpBrains Leave a Comment

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes):

Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used to progress the company’s arti­fi­cial intel­li­gence-enabled brain bio­mark­er plat­form and launch new clin­i­cal tri­als in areas of high unmet med­ical need. Alto will report Phase 2a data in ear­ly 2023 and fur­ther antic­i­pates Phase 2b data read­outs by ear­ly 2024. [Read more…] about Pre­ci­sion psy­chi­a­try pio­neer Alto Neu­ro­science rais­es $35M to advance dig­i­tal bio­mark­er-to-treat­ment platform

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Alto Neuroscience, Amit Etkin, artificial intelligence, brain biomarker, EEG activity, Major Depressive Disorder, neuro-tech, precision psychiatry

AI-enabled chatbot Wysa receives FDA Breakthrough Device designation for patients with chronic pain, depression and anxiety

June 6, 2022 by SharpBrains

AI Behav­ior Health Chat­bot App Fast-Tracked by FDA (Psy­chol­o­gy Today):

Recent­ly the U.S. Food and Drug Admin­is­tra­tion (FDA) grant­ed break­through device des­ig­na­tion to Wysa’s AI-based dig­i­tal men­tal health con­ver­sa­tion­al agent that deliv­ers cog­ni­tive behav­ioral ther­a­py (CBT) via a smart­phone to adults suf­fer­ing from depres­sion, anx­i­ety, and chron­ic mus­cu­loskele­tal pain [Read more…] about AI-enabled chat­bot Wysa receives FDA Break­through Device des­ig­na­tion for patients with chron­ic pain, depres­sion and anxiety

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: anxiety, artificial intelligence, CBT, chronic musculoskeletal pain, cognitive-behavioral-therapy, depression, digital mental health, FDA, Food and Drug Administration, mental health industry, smartphone, Wysa

Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

April 12, 2022 by SharpBrains

Research col­lab­o­ra­tion will test nov­el algorithm’s effec­tive­ness on Geisinger data (press release):

Geisinger and Eisai Inc. today announced a col­lab­o­ra­tive effort to study the poten­tial effec­tive­ness of an arti­fi­cial intel­li­gence (AI) tool in the detec­tion of cog­ni­tive impair­ment that could iden­ti­fy demen­tias, includ­ing Alzheimer’s dis­ease (AD). If effec­tive, the AI tool could poten­tial­ly be devel­oped to sup­port the ear­ly detec­tion and stag­ing of cog­ni­tive impair­ment and demen­tia, lead­ing to appro­pri­ate addi­tion­al test­ing for the clin­i­cal, bio­log­i­cal diag­no­sis and treat­ment of demen­tias such as AD. [Read more…] about Geisinger and Eisai to test real-world valid­i­ty of AI-pow­ered Pas­sive Dig­i­tal Mark­er (PDM) in detect­ing ear­ly cog­ni­tive impair­ment and dementia

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: algorithm, Alzheimer’s Disease, artificial intelligence, Cognitive-impairment, dementia, Eisai, electronic medical records, Geisinger, machine-learning, Passive Digital Marker

Mapping ‘psychedelic trips’ in the brain to better direct their therapeutic effects

April 4, 2022 by The Conversation

Image cred­it: Shutterstock

For the past sev­er­al decades, psy­che­delics have been wide­ly stig­ma­tized as dan­ger­ous ille­gal drugs. But a recent surge of aca­d­e­m­ic research into their use to treat psy­chi­atric con­di­tions is spurring a recent shift in pub­lic opinion.

Psy­che­delics are psy­chotrop­ic drugs: sub­stances that affect your men­tal state. Oth­er types of psy­chotrop­ics include anti­de­pres­sants and anti-anx­i­ety med­ica­tions. Psy­che­delics and oth­er types of hal­lu­cino­gens, how­ev­er, are unique in their abil­i­ty to tem­porar­i­ly induce intense hal­lu­ci­na­tions, emo­tions and dis­rup­tions of self-aware­ness. [Read more…] about Map­ping ‘psy­che­del­ic trips’ in the brain to bet­ter direct their ther­a­peu­tic effects

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: academic research, anxiety, artificial intelligence, brain regions, cognitive-flexibility, depression, psychedelics, psychiatric conditions, psychotropic drugs, therapeutic, treat psychiatric conditions

Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform

November 17, 2021 by SharpBrains

Neu­rotech start­up Bea­con Biosig­nals scores $27M to bring AI to EEG analy­sis (Med­C­i­ty News):

Elec­troen­cephalog­ra­phy is a decades-old tech­nique for cap­tur­ing brain activ­i­ty, data that are used to eval­u­ate brain dis­or­ders. Bea­con Biosig­nals is apply­ing arti­fi­cial intel­li­gence to these tests, and the neu­rotech­nol­o­gy start­up has found a ready mar­ket in phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in assess­ing how their exper­i­men­tal brain ther­a­pies are work­ing. Now Bea­con Biosig­nals has some­thing else: $27 mil­lion in financ­ing. [Read more…] about Bea­con Biosig­nals rais­es $27M to scale EEG, AI-based neu­ro­bio­mark­er dis­cov­ery platform

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: artificial intelligence, Beacon Biosignals, brain disorders, brain signatures, brain-activity, Cumulus Neuroscience, EEG, EEG brain signatures, electroencephalography, Kernel, machine-learning, neurobiomarkers, neurotechnologies, Neurotechnology, noninvasive neurotechnologies, noninvasive neurotechnology

AI-powered Woebot raises $90M to scale up digital self-therapy platform

July 26, 2021 by SharpBrains

‘Dig­i­tal ther­a­pist’ Woe­bot perks up with $90M for AI-pow­ered men­tal health plat­form (Fierce­Biotech):

In news sure to excite even the most melan­choly of arti­fi­cial intel­li­gence-pow­ered chat­bots, men­tal health plat­form Woe­bot has closed its series B fund­ing round with a whop­ping $90 mil­lion. [Read more…] about AI-pow­ered Woe­bot rais­es $90M to scale up dig­i­tal self-ther­a­py platform

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Peak Performance, Technology & Innovation Tagged With: artificial intelligence, chatbot, cognitive behavior therapy, dialectical behavior therapy, digital self-therapy, digital therapeutics, interpersonal psychotherapy, mental health care, mental health platform, Woebot Health

Next Page »

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,620 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy